NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses [Yahoo! Finance]
NovaBay Pharmaceuticals, Inc. (NBY)
NASDAQ:AMEX Investor Relations:
novabay.com/investors
Company Research
Source: Yahoo! Finance
EMERYVILLE, Calif., April 17, 2024 BUSINESS WIRE NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company's lead product, Avenova Antimicrobial Lid & Lash Solution. "We started 2024 with strong revenue growth from our core eyecare business while reducing marketing spend by capitalizing on our e-marketing expertise," said Justin Hall, CEO of NovaBay. "Investing in direct-to-consumer marketing to leverage our clinical pedigree is a modern approach to the pharmaceutical industry's traditional sales model. We are pleased that our social media programs are efficiently establishing consumer trust in the Avenova brand as eyecare professionals engage with new pot
Show less
Read more
Impact Snapshot
Event Time:
NBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBY alerts
High impacting NovaBay Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NBY
News
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales [Yahoo! Finance]Yahoo! Finance
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesBusiness Wire
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity [Yahoo! Finance]Yahoo! Finance
NBY
Sec Filings
- 4/22/24 - Form 8-K
- 4/19/24 - Form 8-K
- 4/18/24 - Form ARS
- NBY's page on the SEC website